Early stage clinical trial to investigate whether the Oxabact OC5 product reduces oxalate levels in the blood of patients with primary hyperoxaluria(a disease affecting the kidneys) who are on dialysis

Phase 1

• Conditions: Primary Hyperoxaluria (PH); MedDRA version: 20.1Level: PTClassification code 10020703Term: HyperoxaluriaSystem Organ Class: 10038359 - Renal and urinary disorders; Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]

• Registration Number: EUCTR2013-004368-74-DE
• Lead Sponsor: OxThera Intellectual Property AB

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2013-11-19
• Study Completion: 2020-01-29
• Last Update Posted: 23 November 2020

Recruitment & Eligibility

• Status: ot Recruiting
• Sex: All
• Target Recruitment: 12

Inclusion Criteria

1.Signed informed consent (as applicable for the age of the patient). An appendix to the informed consent form will be signed by patients continuing on treatment after week 14.
2.Male or female patients = 2 years of age. Patients have to be able to swallow size 4 capsules twice daily, or use a gastric tube that allows for administration of size 4 capsules.
3.A diagnosis of PH (as determined by standard diagnostic methods).
4.Patient should be on a stable dialysis regimen for at least two weeks before baseline.
5.Plasma oxalate =40 micromole/L prior to the dialysis session.
6.Patients receiving vitamin B6 must be receiving a stable dose for at least 3 months prior to screening and must remain on the stable dose during the study. Patients not receiving vitamin B6 at study entry must be willing to refrain from initiating vitamin B6 during study participation.
Are the trial subjects under 18? yes
Number of subjects for this age range: 1
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 11
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

7.Inability to swallow size 4 capsules twice daily, or using a gastric tube not suited for administration of size 4 capsules via the tube.
8.Ongoing treatment with immunosuppressive medication.
9.The existence of secondary hyperoxaluria, e.g. hyperoxaluria due to bariatric surgery or chronic gastrointestinal diseases such as cystic fibrosis, chronic inflammatory bowel disease and short-bowel syndrome.
10.Use of antibiotics to which O. formigenes is sensitive (see section 7.2.2), including current antibiotic use, or antibiotics use within 14 days of initiating study medication.
11.Current treatment with a separate ascorbic acid preparation. Standard of care vitamin supplement for patients on dialysis are allowed.
12.Pregnancy.
13.Women of childbearing potential who are not using adequate contraceptive precautions. Sexually active females, unless surgically sterile or at least 2 years post-menopausal, must be using a highly effective contraception (including oral, transdermal, injectable, or implanted contraceptives, IUD, abstinence, use of a condom by the sexual partner or sterile sexual partner) for 30 days prior to the first dose of OC5 and must agree to continue using such precautions during the clinical study.
14.Presence of a medical condition that the Principal Investigator considers likely to make the patient susceptible to adverse effect of study treatment or unable to follow study procedures.
15.Participation in any study of an investigational product, biologic, device, or other agent within 30 days prior to the first dose of OC5 or not willing to forego other forms of investigational treatment during this study.

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified